MGIA
ENSC icon

Moneta Group Investment Advisors’s Ensysce Biosciences ENSC Stock Holding History

Moneta Group Investment Advisors’s Portfolio ENSC Stock Details ENSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1
Closed -$22K – 462
2022
Q3 		$22K Buy
+1
New +$1.63K ﹤0.01% 426

Other funds holding ENSC

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Moneta Group Investment Advisors's ENSC Position: Q4 2022 in Review

Moneta Group Investment Advisors sold out of Ensysce Biosciences (ENSC) in Q4 2022, closing a stake of 1 share — an estimated $22K sold.

Moneta Group Investment Advisors first reported a position in ENSC in Q3 2022 and held it in 1 quarter. The position peaked at $22K in Q3 2022. 13 funds tracked by Wall St. Rank hold ENSC as of Q4 2022.

  • Moneta Group Investment Advisors reported no remaining Ensysce Biosciences position as of Q4 2022 after selling out during the quarter.
  • Moneta Group Investment Advisors sold 1 Ensysce Biosciences share in Q4 2022, an estimated $22K.
  • Moneta Group Investment Advisors first reported a position in Ensysce Biosciences in Q3 2022 and held it in 1 quarter.
  • Moneta Group Investment Advisors's Ensysce Biosciences position peaked at $22K in Q3 2022.
  • 13 funds tracked by Wall St. Rank held Ensysce Biosciences as of Q4 2022.

Based on Moneta Group Investment Advisors's 13F filing for Q4 2022, filed 15 Feb 2023.